

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
33186	15/SW/0196	181754	CANC - 4663 - Phase III Study of MPDL3280A in Stage IV Non-Squamous NSCLC	Number Agreed	2	2	Date Agreed	31/08/2016	5	02/02/2018	5	Recruitment Finished	
33187	15/NW/0492	181246	CANC - 4603 - ACP-196 vs Ibrutinib in Previously Treated Subjects with High Risk CLL	Number Agreed	4	4	Date Agreed	31/10/2017	7	31/10/2017	7	Recruitment Finished	
33188	15/LO/1289	181953	CARD 3867 VOYAGER	Number Agreed	20	20	Date Agreed	31/12/2017	4	12/12/2017	4	Recruitment Finished	
33189	15/LO/1105	181406	CANC 4277	Number Agreed	2	2	Date Agreed	01/05/2017	1	02/03/2018	1	Recruitment Finished	
33190	15/SW/0248	186033	VX14-661-110 Cystic Fibrosis	Number Agreed	3	3	Date Agreed	16/07/2018	10	30/06/2018	10	Recruitment Finished	
33191	16/WM/0170	195010	META 5539	Number Agreed	1	1	Date Agreed	29/12/2017	4	29/12/2017	4	Recruitment Finished	
33192	15/LO/2045	193136	CHIL 5229 SMT C1100 in Ambulatory Boys with DMD	Number Agreed	2	2	Date Agreed	02/03/2017	5	27/06/2018	5	Recruitment Finished	
33193	15/EM/0521	184930	CANC - 5309	Number Agreed	4	4	Date Agreed	31/07/2018	5	22/06/2018	5	Recruitment Finished	
33194	16/EM/0037	196490	MUSC 4598	Number Agreed	4	4	Date Agreed	19/12/2017	3	30/01/2018	3	Recruitment Finished	
33195	17/LO/0100	200545	A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens	Number Agreed	2	2	Date Agreed	31/05/2018	0	26/03/2018	0	Withdrawn By Sponsor	
33196	13/NW/0003	117310	SEVERE SEPSIS / COAGULOPATHY TRIAL ART-123	Number Agreed	3	3	Date Agreed	31/08/2017	2	08/03/2018	2	Recruitment Finished	
33197	16/WM/0108	195179	CHIL 4885	Number Agreed	5	5	Date Agreed	01/07/2018	0	18/01/2018	0	Withdrawn By Sponsor	
33198	16/EM/0167	179908	RESP 4602	Number Agreed	3	3	Date Agreed	31/01/2019	1	16/07/2018	1	Withdrawn By Sponsor	
33199	16/LO/1717	212505	ACP-196 with Relapsed or Refractory Chronic Lymphocytic Leukemia	Number Agreed	5	5	Date Agreed	01/09/2020	0	12/12/2017	0	Withdrawn By Sponsor	
33200	16/WM/0507	218607	EXCEED	Number Agreed	4	4	Date Agreed	01/06/2018	2	23/08/2018	2	Recruitment Finished	
33201	17/LO/0441	222471	MK-3475-604 (Phase 3 trial of etoposide/platinum with or without pembrolizumab)	Number Agreed	4	4	Date Agreed	30/09/2021	1	09/07/2018	1	Withdrawn By Sponsor	
33203	17/WA/0183	225334	M16-043 Phase 3 patients with treatment naive AML	Number Agreed	2	2	Date Agreed	22/08/2019	3	19/04/2018	3	Recruitment Finished	
33204	17/LO/0683	226533	VXECD101	Number Agreed	2	2	Date Agreed	23/02/2018	4	29/12/2017	4	Recruitment Finished	
33205	16/SW/0044	198004	CANC 5248	Number Agreed	3	3	Date Agreed	28/01/2020	0	19/12/2017	0	Withdrawn By Sponsor	
33206	16/SC/0035	194232	A Phase III Study of Pembrolizumab vs. Chemotherapy in MSI-H or dMMR S	Number Agreed	3	3	Date Agreed	30/04/2018	1	30/04/2018	1	Recruitment Finished	
33207	17/NW/0584	233211	Study of Serlopitant for the Treatment of Refractory Chronic Cough	Number Agreed	5	5	Date Agreed	30/04/2018	1	30/04/2018	1	Recruitment Finished	
33208	16/LO/1709	212830	Semaglutide in NASH	Number Agreed	2	2	Date Agreed	19/11/2018	0	19/07/2018	0	Withdrawn By Sponsor	
33209	18/SC/0098	241440	Subcut Daratumumab in combination with standard treatment regimens	Number Agreed	3	3	Date Agreed	27/10/2020	5	22/08/2018	5	Recruitment Finished	